Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.


We use our state-of-the-art dedicated workflow for designing focused libraries.


 

Fig. 1. The screening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P31689

UPID:
DNJA1_HUMAN

ALTERNATIVE NAMES:
DnaJ protein homolog 2; HSDJ; Heat shock 40 kDa protein 4; Heat shock protein J2; Human DnaJ protein 2

ALTERNATIVE UPACC:
P31689; Q5T7Q0; Q86TL9

BACKGROUND:
The protein DnaJ homolog subfamily A member 1, also referred to as Heat shock 40 kDa protein 4, is integral to the cellular machinery for handling protein folding and stress. It assists in ATP hydrolysis without directly folding proteins and is pivotal in transporting proteins into mitochondria. Its role extends to apoptosis, where it acts as a co-chaperone to prevent or promote cell death under stress conditions.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of DnaJ homolog subfamily A member 1 offers a pathway to novel therapeutic avenues. Its dual role in apoptosis and mitochondrial function highlights its potential as a therapeutic target in conditions where these processes are compromised.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.